{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:07:52Z","timestamp":1784693272204,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.pharma.2024.01.001","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T17:03:58Z","timestamp":1704992638000},"page":"545-552","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Antibacterial agents and the fight against antibiotic resistance: A real-world evidence analysis of consumption and spending by an Italian healthcare company"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9298-6783","authenticated-orcid":false,"given":"Francesco","family":"Ferrara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9488-6057","authenticated-orcid":false,"given":"Maurizio","family":"Capuozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Pasquinucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Langella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"Trama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Nava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6528-2171","authenticated-orcid":false,"given":"Andrea","family":"Zovi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2024.01.001_bib0005","series-title":"Health emergency preparedness and response authority","author":"European Commission","year":"2023"},{"key":"10.1016\/j.pharma.2024.01.001_bib0010","unstructured":"European Centre for Disease Prevention and Control, 2022 https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/Health-burden-infections-antibiotic-resistantbacteria.pdf. 2022. [Accessed October 2023]."},{"key":"10.1016\/j.pharma.2024.01.001_bib0015","unstructured":"Italian superior institute of health. 2019. https:\/\/www.iss.it\/one-health [accessed October 2023]."},{"key":"10.1016\/j.pharma.2024.01.001_bib0020","unstructured":"Consiglio unione europea bruxelles 1 giugno 2023 - \u201cRaccomandazione del Consiglio sul potenziamento delle azioni dell\u2019UE per combattere la resistenza antimicrobica con un approccio \u201cOne Health\u201d.2023."},{"key":"10.1016\/j.pharma.2024.01.001_bib0025","series-title":"Piano Nazionale di Contrasto all\u2019Antibiotico-Resistenza (PNCAR) 2022-2025","author":"Italian Ministry of Health","year":"2022"},{"key":"10.1016\/j.pharma.2024.01.001_bib0030","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/jac\/dkn150","article-title":"Antibiotic use in 26 departments of internal medicine in 6 general hospitals in Israel: variability and contributing factors","volume":"62","author":"Shalit","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pharma.2024.01.001_bib0035","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s15010-008-7462-z","article-title":"Quantitative antibiotic use in hospitals: comparison of measurements, literature review, and recommendations for a standard of reporting","volume":"36","author":"Kuster","year":"2008","journal-title":"Infection"},{"key":"10.1016\/j.pharma.2024.01.001_bib0040","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1086\/589333","article-title":"Differential correlation between rates of antimicrobial drug consumption and prevalence of antimicrobial resistance in a tertiary care hospital in Greece","volume":"29","author":"Iosifidis","year":"2008","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"1","key":"10.1016\/j.pharma.2024.01.001_bib0045","doi-asserted-by":"crossref","first-page":"e2016036","DOI":"10.4084\/mjhid.2016.036","article-title":"Surveillance and control of antibiotic resistance in the Mediterranean region","volume":"8","author":"Ricciardi","year":"2016","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"3","key":"10.1016\/j.pharma.2024.01.001_bib0050","first-page":"126","article-title":"Quinolone-induced psychosis: an updated review","volume":"48","author":"Palma-Alvarez","year":"2020","journal-title":"Actas Esp Psiquiatr"},{"key":"10.1016\/j.pharma.2024.01.001_bib0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2334-14-13","article-title":"A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance","volume":"14","author":"Bell","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.pharma.2024.01.001_bib0060","doi-asserted-by":"crossref","first-page":"11387","DOI":"10.3389\/bjbs.2023.11387","article-title":"Antimicrobial resistance (AMR)","volume":"80","author":"Tang","year":"2023","journal-title":"Br J Biomed Sci"},{"key":"10.1016\/j.pharma.2024.01.001_bib0065","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijid.2022.06.013","article-title":"Changes in antibiotic consumption patterns after the implementation of the National Action Plan according to the Access, Watch, Reserve (AWaRe) classification system","volume":"122","author":"Chae","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"2","key":"10.1016\/j.pharma.2024.01.001_bib0070","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2174\/2772434417666220720111849","article-title":"Vigilance needed in treating leprosy patients in accordance with WHO's AWaRe","volume":"17","author":"Thangaraju","year":"2022","journal-title":"Recent Adv Antiinfect Drug Discov"},{"issue":"11","key":"10.1016\/j.pharma.2024.01.001_bib0075","doi-asserted-by":"crossref","first-page":"e851","DOI":"10.1016\/S2666-5247(23)00343-9","article-title":"AMR is more complicated than a lack of drugs","volume":"4","author":"The Lancet Microbe","year":"2023","journal-title":"Lancet Microbe"},{"issue":"Suppl. 7","key":"10.1016\/j.pharma.2024.01.001_bib0080","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1093\/cid\/ciz830","article-title":"Treatment options for carbapenem-resistant Gram-negative bacterial infections","volume":"69","author":"Doi","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pharma.2024.01.001_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharma.2023.02.003","article-title":"SARS-CoV-2 caused a surge in antibiotic consumption causing a silent pandemic inside the pandemic. A retrospective analysis of Italian data in the first half of 2022","author":"Ferrara","year":"2023","journal-title":"Ann Pharm Fr"},{"issue":"5","key":"10.1016\/j.pharma.2024.01.001_bib0090","first-page":"277","article-title":"Il contrasto dell\u2019antibiotico-resistenza: serve una nuova linea di azione [Countering antibiotic resistance: a new course of action is needed.]","volume":"114","author":"Ferrara","year":"2023","journal-title":"Recenti Prog Med"},{"issue":"7","key":"10.1016\/j.pharma.2024.01.001_bib0095","first-page":"e41414","article-title":"Antibiotic consumption in primary care in Costa Rica and Italy: a retrospective cross-country analysis","volume":"15","author":"Zavaleta","year":"2023","journal-title":"Cureus"},{"issue":"11","key":"10.1016\/j.pharma.2024.01.001_bib0100","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.3855\/jidc.17148","article-title":"Antibiotic consumption in hospitals during COVID-19 pandemic: a comparative study","volume":"16","author":"Hussein","year":"2022","journal-title":"J Infect Dev Ctries"},{"issue":"8","key":"10.1016\/j.pharma.2024.01.001_bib0105","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3390\/antibiotics10080943","article-title":"Catalan Infection Control and Antimicrobial Stewardship Program (VINCat-PROA). Antimicrobial consumption among 66 acute care hospitals in Catalonia: Impact of the COVID-19 pandemic","volume":"10","author":"Grau","year":"2021","journal-title":"Antibiotics (Basel)"},{"issue":"3","key":"10.1016\/j.pharma.2024.01.001_bib0110","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.cmi.2022.12.006","article-title":"Antibiotic resistance associated with the COVID-19 pandemic: a systematic review and meta-analysis","volume":"29","author":"Langford","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.pharma.2024.01.001_bib0115","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s12012-021-09649-y","article-title":"Scientific hypothesis for treatment of COVID-19's lung lesions by adjusting ACE\/ACE2 imbalance","volume":"21","author":"Ferrara","year":"2021","journal-title":"Cardiovasc Toxicol"},{"issue":"4","key":"10.1016\/j.pharma.2024.01.001_bib0120","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jiph.2023.02.021","article-title":"A parallel and silent emerging pandemic: Antimicrobial resistance (AMR) amid COVID-19 pandemic","volume":"16","author":"Rehman","year":"2023","journal-title":"J Infect Public Health"},{"issue":"4","key":"10.1016\/j.pharma.2024.01.001_bib0125","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/00185787211069040","article-title":"Could decreased reporting of suspected adverse reactions generate future safety concerns?","volume":"57","author":"Ferrara","year":"2022","journal-title":"Hosp Pharm"},{"issue":"1","key":"10.1016\/j.pharma.2024.01.001_bib0130","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12026-021-09244-x","article-title":"A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy?","volume":"70","author":"Vitiello","year":"2022","journal-title":"Immunol Res"},{"issue":"12","key":"10.1016\/j.pharma.2024.01.001_bib0135","doi-asserted-by":"crossref","first-page":"e51034","DOI":"10.15252\/embr.202051034","article-title":"Antibiotic resistance and persistence-Implications for human health and treatment perspectives","volume":"21","author":"Huemer","year":"2020","journal-title":"EMBO Rep"},{"issue":"1","key":"10.1016\/j.pharma.2024.01.001_bib0140","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","article-title":"Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies","volume":"37","author":"Pang","year":"2019","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.pharma.2024.01.001_bib0145","doi-asserted-by":"crossref","first-page":"900848","DOI":"10.3389\/fcimb.2022.900848","article-title":"Link between antibiotic persistence and antibiotic resistance in bacterial pathogens","volume":"12","author":"Eisenreich","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"issue":"8","key":"10.1016\/j.pharma.2024.01.001_bib0150","doi-asserted-by":"crossref","first-page":"e026072","DOI":"10.1136\/bmjopen-2018-026072","article-title":"Impact of antimicrobial stewardship managed by clinical pharmacists on antibiotic use and drug resistance in a Chinese hospital, 2010-2016: a retrospective observational study","volume":"9","author":"Wang","year":"2019","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.pharma.2024.01.001_bib0155","doi-asserted-by":"crossref","first-page":"581e1","DOI":"10.1016\/j.japh.2021.04.013","article-title":"Antimicrobial stewardship solutions with a smart innovative tool","volume":"61","author":"Shawki","year":"2021","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"5","key":"10.1016\/j.pharma.2024.01.001_bib0160","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/00185787221074570","article-title":"The slow path to therapeutic adherence","volume":"57","author":"Ferrara","year":"2022","journal-title":"Hosp Pharm"},{"issue":"12","key":"10.1016\/j.pharma.2024.01.001_bib0165","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1177\/10600280221082326","article-title":"Ceftaroline: systematic review of clinical uses and emerging drug resistance","volume":"56","author":"Abate","year":"2022","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.pharma.2024.01.001_bib0170","article-title":"Recovery of suspended reimbursements of high-cost drugs subjected to monitoring registries and negotiated agreements (MEAs): a tool for governance and clinical appropriateness in the Italian reality","author":"Capuozzo","year":"2023","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.pharma.2024.01.001_bib0175","article-title":"Study of overall survival associated with nintedanib and pirfenidone in patients with idiopathic pulmonary fibrosis: a real-life comparison","author":"Mazzoleni","year":"2022","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.pharma.2024.01.001_bib0180","doi-asserted-by":"crossref","DOI":"10.1080\/20479700.2023.2273025","article-title":"Atrial fibrillation therapy with new oral anticoagulants: a real-world evidence study","author":"Ferrara","year":"2023","journal-title":"Int J Healthcare Manage"},{"key":"10.1016\/j.pharma.2024.01.001_bib0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/20479700.2023.2273025","article-title":"New drugs for type 2 diabetes mellitus: The challenge of the health care sustainability combined with a better patient care access","volume":"1","author":"Ferrara","year":"2023","journal-title":"Int J Healthcare Manage"},{"key":"10.1016\/j.pharma.2024.01.001_bib0190","series-title":"National report on antibiotics use in Italy, 2021","author":"The Medicines Utilisation Monitoring Centre","year":"2023"},{"issue":"6","key":"10.1016\/j.pharma.2024.01.001_bib0195","first-page":"317","volume":"28","author":"Collado","year":"2015","journal-title":"Rev Esp Quimioter"},{"issue":"34","key":"10.1016\/j.pharma.2024.01.001_bib0200","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2019.24.34.1900022","article-title":"Antimicrobial use trends, Israel, 2012 to 2017","volume":"24","author":"Dickstein","year":"2019","journal-title":"Euro Surveill"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450924000014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450924000014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T22:33:30Z","timestamp":1731018810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450924000014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0003450924000014"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2024.01.001","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibacterial agents and the fight against antibiotic resistance: A real-world evidence analysis of consumption and spending by an Italian healthcare company","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2024.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}